IGHV7-34-1: Potential Drug Or Biomarker (G28382)

Target Name: IGHV7-34-1

NCBI ID: G28382

IGHV7-34-1

Other Name(s): 7-34.1P | immunoglobulin heavy variable 7-34-1 (pseudogene) | Immunoglobulin heavy variable 7-34-1 (pseudogene) | IGHV7341

IGHV7-34-1: Potential Drug Or Biomarker

IGHV7-34-1 (7-34.1P), also known as human interleukin-7 (IL-7), is a cytokine that plays a crucial role in the immune system. It is a type of cytokine that is produced by various immune cells, including T-cells, B-cells, and natural killer cells. IL-7 is a key regulator of immune responses and has been implicated in the development and progression of various diseases, including cancer, autoimmune disorders, and inflammatory diseases.

The research on IGHV7-34-1 has been ongoing for several decades, and there is a growing interest in it as a potential drug target or biomarker. IGHV7-34-1 has been shown to play a key role in the regulation of immune responses, and it has been shown to have a negative impact on cancer growth and progression.

One of the key functions of IGHV7-34-1 is its ability to stimulate the production ofIL-12, a cytokine that is involved in the regulation of immune responses. IL-12 is responsible for the development and activation of T-cells, which are a crucial part of the immune system. By stimulating the production of IL-12, IGHV7-34-1 helps to ensure that the immune system is able to effectively fight off infections and diseases.

IGHV7-34-1 has also been shown to play a key role in the regulation of cell death. It has been shown to induce cell death, either through apoptosis or through a process called necroptosis. This process is regulated by the cell's own programs for cell death, and it is a crucial part of the immune system's response to infection and disease.

In addition to its role in immune regulation, IGHV7-34-1 has also been shown to have a negative impact on cancer growth and progression. It has been shown to inhibit the growth of cancer cells in a variety of models, including in vitro and in animal models. This suggests that IGHV7-34-1 may be an effective target for cancer treatment.

Despite the potential benefits of IGHV7-34-1 as a drug or biomarker, there are also concerns about its potential drawbacks. For example, IGHV7-34-1 has been shown to cause some adverse effects in animal models, including increased blood pressure and decreased levels of red blood cells. It is important to further research and develop these concerns before IGHV7-34-1 can be considered as a safe and effective drug or biomarker.

In conclusion, IGHV7-34-1 (7-34.1P) is a cytokine that plays a crucial role in the immune system. It is a key regulator of immune responses and has been shown to have a negative impact on cancer growth and progression. Further research is needed to fully understand its potential as a drug or biomarker.

Protein Name: Immunoglobulin Heavy Variable 7-34-1 (pseudogene)

The "IGHV7-34-1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHV7-34-1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets